Bugworks Research Inc. aims to tackle this global Anti-microbial Resistance (AMR) crisis by developing a novel class of antibiotics exhibiting broad-spectrum activity against Gram-negative and Gram-positive infections. Using the proprietary platform, Bugworks has come up with a first-in-class antibiotic series named GYROX that is effective on all known classes of drug-resistant bacteria. Bugworks is the first Asian company to win the prestigious CARB‑X grant, amounting to over $10M.
Date- 26th November
Time- 6 – 7 pm IST
Registration link — https://lnkd.in/g3M-cFAf